Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Authors
Okusaka, T.Kitano, M.
Chen, M. H.
Chen, J. S.
Ostwal, V. S.
McNamara, Mairead G
Breder, V.
Petrova, M.
Buchschacher, G.
Rokutanda, N.
Xiong, J.
Cohen, G.
Oh, D. Y.
Affiliation
Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo,JapanIssue Date
2022
Metadata
Show full item recordCitation
Okusaka T, Kitano M, Chen MH, Chen JS, Ostwal VS, McNamara MG, et al. Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study. Annals of Oncology. 2022 Nov;38(9):S1471-S. PubMed PMID: WOS:000897943700095.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.10.129Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.10.129Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.10.129